Dr. Gearóid Tuohy

Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients.  The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.

A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.

A team of clinical researchers based at Johns Hopkins Hospital, Baltimore, Maryland, has reported findings of equivalent efficacy and similar safety and immunogenicity profiles with… Read More »A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.

Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.

Clinical researchers at the NHS Foundation Trust, Sheffield, UK have found that real-world evidence on the effectiveness and safety of a fluocinolone acetonide (FAc) implant… Read More »Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.